Jeanelle Sheeder
Concepts (633)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Contraception | 19 | 2024 | 170 | 6.420 |
Why?
| | Contraceptive Agents, Female | 26 | 2024 | 80 | 4.130 |
Why?
| | Family Planning Services | 12 | 2023 | 93 | 3.180 |
Why?
| | Contraception Behavior | 19 | 2024 | 108 | 3.080 |
Why?
| | Desogestrel | 22 | 2024 | 46 | 3.020 |
Why?
| | Contraceptive Agents | 7 | 2023 | 66 | 3.020 |
Why?
| | Pregnancy in Adolescence | 18 | 2024 | 82 | 2.900 |
Why?
| | Abortion, Induced | 15 | 2025 | 111 | 2.850 |
Why?
| | Pregnancy | 82 | 2025 | 7215 | 2.250 |
Why?
| | Long-Acting Reversible Contraception | 9 | 2024 | 34 | 2.230 |
Why?
| | Drug Implants | 20 | 2024 | 83 | 1.850 |
Why?
| | Prenatal Care | 9 | 2020 | 309 | 1.780 |
Why?
| | Hospitals, Religious | 5 | 2020 | 5 | 1.560 |
Why?
| | Gynecology | 11 | 2026 | 181 | 1.550 |
Why?
| | Adolescent Health Services | 4 | 2024 | 74 | 1.500 |
Why?
| | Counseling | 6 | 2020 | 401 | 1.440 |
Why?
| | Intrauterine Devices | 7 | 2019 | 29 | 1.410 |
Why?
| | Female | 175 | 2026 | 79025 | 1.410 |
Why?
| | Health Knowledge, Attitudes, Practice | 12 | 2025 | 1419 | 1.410 |
Why?
| | Postpartum Period | 11 | 2024 | 373 | 1.410 |
Why?
| | Adolescent | 91 | 2025 | 22569 | 1.390 |
Why?
| | Young Adult | 68 | 2025 | 14250 | 1.320 |
Why?
| | Obstetrics | 9 | 2026 | 177 | 1.310 |
Why?
| | Adolescent Behavior | 9 | 2015 | 497 | 1.290 |
Why?
| | Pregnancy Outcome | 10 | 2025 | 504 | 1.100 |
Why?
| | Colorado | 36 | 2025 | 4556 | 1.070 |
Why?
| | Humans | 192 | 2026 | 145750 | 1.070 |
Why?
| | Reproductive Health | 4 | 2023 | 91 | 1.060 |
Why?
| | Catholicism | 5 | 2020 | 9 | 1.030 |
Why?
| | Contraception, Postcoital | 2 | 2025 | 9 | 1.030 |
Why?
| | Endometrial Neoplasms | 10 | 2022 | 205 | 1.030 |
Why?
| | Chlamydia Infections | 3 | 2024 | 79 | 1.030 |
Why?
| | Health Personnel | 2 | 2025 | 755 | 0.970 |
Why?
| | Contraceptives, Oral, Combined | 2 | 2023 | 18 | 0.890 |
Why?
| | Adult | 95 | 2026 | 40867 | 0.880 |
Why?
| | Postnatal Care | 3 | 2021 | 76 | 0.840 |
Why?
| | Cross-Sectional Studies | 26 | 2026 | 5921 | 0.830 |
Why?
| | Trichomonas Infections | 1 | 2024 | 11 | 0.820 |
Why?
| | Trichomonas vaginalis | 1 | 2024 | 11 | 0.820 |
Why?
| | Substance Abuse Detection | 1 | 2025 | 110 | 0.810 |
Why?
| | Patient Acceptance of Health Care | 3 | 2020 | 883 | 0.810 |
Why?
| | Confidentiality | 1 | 2024 | 80 | 0.790 |
Why?
| | Patient Satisfaction | 6 | 2025 | 712 | 0.790 |
Why?
| | Surveys and Questionnaires | 27 | 2026 | 6084 | 0.780 |
Why?
| | Healthcare Disparities | 3 | 2025 | 736 | 0.780 |
Why?
| | Sexual Behavior | 7 | 2022 | 495 | 0.780 |
Why?
| | Enoxaparin | 2 | 2020 | 68 | 0.760 |
Why?
| | Religion and Medicine | 3 | 2020 | 33 | 0.710 |
Why?
| | Pyridones | 2 | 2020 | 209 | 0.690 |
Why?
| | Sexually Transmitted Diseases | 1 | 2024 | 168 | 0.690 |
Why?
| | Levonorgestrel | 4 | 2018 | 34 | 0.650 |
Why?
| | Parity | 5 | 2016 | 111 | 0.630 |
Why?
| | Ambulatory Care Facilities | 5 | 2024 | 269 | 0.620 |
Why?
| | Group Processes | 2 | 2018 | 63 | 0.620 |
Why?
| | Mothers | 5 | 2022 | 765 | 0.610 |
Why?
| | Religion and Psychology | 1 | 2019 | 27 | 0.600 |
Why?
| | Hysterectomy | 6 | 2019 | 138 | 0.600 |
Why?
| | Pyrazoles | 2 | 2020 | 517 | 0.600 |
Why?
| | Health Services Accessibility | 5 | 2026 | 1101 | 0.600 |
Why?
| | Postoperative Hemorrhage | 1 | 2020 | 105 | 0.590 |
Why?
| | Venous Thromboembolism | 2 | 2020 | 328 | 0.580 |
Why?
| | Patient-Centered Care | 2 | 2021 | 547 | 0.580 |
Why?
| | Sex Offenses | 1 | 2022 | 196 | 0.570 |
Why?
| | Intention | 5 | 2024 | 186 | 0.570 |
Why?
| | Pregnancy Rate | 2 | 2017 | 81 | 0.570 |
Why?
| | Community Health Services | 2 | 2023 | 231 | 0.570 |
Why?
| | Vulnerable Populations | 1 | 2020 | 176 | 0.550 |
Why?
| | Financial Support | 1 | 2018 | 18 | 0.550 |
Why?
| | Health Care Sector | 1 | 2018 | 26 | 0.550 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1372 | 0.550 |
Why?
| | Intrauterine Devices, Copper | 5 | 2018 | 7 | 0.550 |
Why?
| | Rural Health Services | 1 | 2019 | 138 | 0.550 |
Why?
| | Ovarian Neoplasms | 6 | 2020 | 595 | 0.540 |
Why?
| | Pregnancy, Unplanned | 3 | 2017 | 48 | 0.540 |
Why?
| | Prosthesis Implantation | 2 | 2017 | 154 | 0.520 |
Why?
| | Fibrinolytic Agents | 1 | 2020 | 297 | 0.520 |
Why?
| | Premature Birth | 2 | 2025 | 390 | 0.500 |
Why?
| | Retrospective Studies | 36 | 2025 | 17322 | 0.500 |
Why?
| | Luteal Phase | 1 | 2017 | 51 | 0.500 |
Why?
| | Intrauterine Devices, Medicated | 6 | 2017 | 27 | 0.490 |
Why?
| | Delivery of Health Care | 2 | 2023 | 947 | 0.490 |
Why?
| | Chlamydia trachomatis | 3 | 2024 | 49 | 0.490 |
Why?
| | Infant, Low Birth Weight | 2 | 2015 | 156 | 0.480 |
Why?
| | Lacerations | 3 | 2022 | 40 | 0.460 |
Why?
| | Parenting | 1 | 2020 | 319 | 0.460 |
Why?
| | Depression, Postpartum | 3 | 2020 | 116 | 0.460 |
Why?
| | Substance-Related Disorders | 1 | 2025 | 1102 | 0.460 |
Why?
| | Interprofessional Relations | 1 | 2018 | 276 | 0.460 |
Why?
| | Life Style | 4 | 2024 | 486 | 0.450 |
Why?
| | Group Structure | 1 | 2015 | 2 | 0.450 |
Why?
| | Guatemala | 3 | 2021 | 343 | 0.440 |
Why?
| | Risk | 2 | 2017 | 923 | 0.440 |
Why?
| | Perimenopause | 1 | 2015 | 69 | 0.440 |
Why?
| | Carcinoma, Endometrioid | 3 | 2022 | 49 | 0.440 |
Why?
| | Genital Neoplasms, Female | 4 | 2020 | 99 | 0.430 |
Why?
| | Fertility Preservation | 3 | 2023 | 55 | 0.420 |
Why?
| | Uterus | 1 | 2015 | 228 | 0.420 |
Why?
| | Safety-net Providers | 1 | 2015 | 130 | 0.400 |
Why?
| | Multicenter Studies as Topic | 1 | 2015 | 413 | 0.400 |
Why?
| | Patient Selection | 3 | 2015 | 739 | 0.400 |
Why?
| | Maternal Age | 3 | 2018 | 128 | 0.400 |
Why?
| | Middle Aged | 41 | 2026 | 36297 | 0.400 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2019 | 1751 | 0.390 |
Why?
| | Attitude to Health | 3 | 2020 | 430 | 0.380 |
Why?
| | Quality Improvement | 5 | 2025 | 1296 | 0.370 |
Why?
| | Goals | 1 | 2014 | 185 | 0.370 |
Why?
| | Primary Health Care | 4 | 2023 | 1736 | 0.370 |
Why?
| | Choice Behavior | 3 | 2019 | 180 | 0.360 |
Why?
| | Estradiol | 1 | 2015 | 515 | 0.350 |
Why?
| | Uterine Cervical Neoplasms | 3 | 2021 | 268 | 0.350 |
Why?
| | Mass Screening | 9 | 2023 | 1361 | 0.350 |
Why?
| | Papillomavirus Vaccines | 1 | 2015 | 296 | 0.340 |
Why?
| | Internship and Residency | 6 | 2023 | 1269 | 0.340 |
Why?
| | Progesterone | 2 | 2025 | 215 | 0.340 |
Why?
| | Delivery, Obstetric | 5 | 2025 | 160 | 0.330 |
Why?
| | Gestational Age | 5 | 2024 | 989 | 0.330 |
Why?
| | Obstetric Labor Complications | 2 | 2022 | 38 | 0.330 |
Why?
| | Child | 19 | 2024 | 22738 | 0.330 |
Why?
| | Disclosure | 2 | 2022 | 84 | 0.320 |
Why?
| | Postoperative Complications | 9 | 2020 | 2977 | 0.310 |
Why?
| | Magnetoencephalography | 13 | 2000 | 161 | 0.310 |
Why?
| | United States | 20 | 2025 | 16122 | 0.310 |
Why?
| | Functional Laterality | 11 | 2001 | 240 | 0.300 |
Why?
| | Male | 47 | 2025 | 72992 | 0.300 |
Why?
| | Health Behavior | 1 | 2015 | 789 | 0.300 |
Why?
| | Socioeconomic Factors | 5 | 2021 | 1327 | 0.300 |
Why?
| | Lymph Nodes | 3 | 2018 | 509 | 0.290 |
Why?
| | Nurse Midwives | 2 | 2020 | 43 | 0.290 |
Why?
| | Feasibility Studies | 7 | 2022 | 1115 | 0.290 |
Why?
| | Condoms | 3 | 2017 | 102 | 0.290 |
Why?
| | Attitude of Health Personnel | 3 | 2024 | 1196 | 0.290 |
Why?
| | Evoked Potentials, Auditory | 10 | 2001 | 181 | 0.290 |
Why?
| | Birth Intervals | 2 | 2019 | 23 | 0.290 |
Why?
| | Robotic Surgical Procedures | 3 | 2016 | 185 | 0.280 |
Why?
| | Intrauterine Device Expulsion | 3 | 2017 | 9 | 0.270 |
Why?
| | Communication | 3 | 2022 | 976 | 0.270 |
Why?
| | Patient Participation | 1 | 2012 | 440 | 0.270 |
Why?
| | Infant, Small for Gestational Age | 2 | 2019 | 118 | 0.270 |
Why?
| | Women's Health | 2 | 2020 | 316 | 0.260 |
Why?
| | Time Factors | 12 | 2024 | 7133 | 0.260 |
Why?
| | Sexual Partners | 3 | 2024 | 193 | 0.260 |
Why?
| | Attitude | 3 | 2019 | 259 | 0.260 |
Why?
| | Prediabetic State | 2 | 2023 | 250 | 0.250 |
Why?
| | Cohort Studies | 11 | 2021 | 6032 | 0.250 |
Why?
| | Uterine Cervicitis | 1 | 2006 | 7 | 0.250 |
Why?
| | Vaccination | 1 | 2015 | 1428 | 0.250 |
Why?
| | Organizational Policy | 2 | 2019 | 78 | 0.240 |
Why?
| | Pregnancy Complications | 4 | 2019 | 603 | 0.240 |
Why?
| | Age Factors | 8 | 2016 | 3346 | 0.230 |
Why?
| | Perineum | 3 | 2022 | 37 | 0.230 |
Why?
| | Analgesia, Obstetrical | 1 | 2025 | 33 | 0.220 |
Why?
| | Marijuana Use | 2 | 2019 | 222 | 0.220 |
Why?
| | Cerclage, Cervical | 1 | 2025 | 11 | 0.220 |
Why?
| | Pregnancy Trimester, First | 4 | 2023 | 139 | 0.220 |
Why?
| | Cesarean Section | 2 | 2025 | 230 | 0.220 |
Why?
| | Prospective Studies | 14 | 2022 | 8075 | 0.220 |
Why?
| | Gelatin | 2 | 2016 | 56 | 0.220 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2023 | 2602 | 0.220 |
Why?
| | Electronics, Medical | 1 | 2004 | 7 | 0.220 |
Why?
| | Perinatal Care | 1 | 2025 | 59 | 0.220 |
Why?
| | Fetal Death | 2 | 2016 | 57 | 0.220 |
Why?
| | Laparotomy | 2 | 2015 | 113 | 0.220 |
Why?
| | Progestins | 1 | 2025 | 66 | 0.210 |
Why?
| | Labor, Induced | 1 | 2025 | 40 | 0.210 |
Why?
| | Aged, 80 and over | 11 | 2021 | 8346 | 0.210 |
Why?
| | Legal Guardians | 1 | 2024 | 10 | 0.210 |
Why?
| | Database Management Systems | 1 | 2004 | 51 | 0.210 |
Why?
| | Weight Gain | 6 | 2021 | 561 | 0.210 |
Why?
| | Depression | 4 | 2023 | 1557 | 0.210 |
Why?
| | Thrombin | 2 | 2016 | 172 | 0.210 |
Why?
| | Midwifery | 1 | 2025 | 66 | 0.210 |
Why?
| | Contact Tracing | 1 | 2024 | 26 | 0.200 |
Why?
| | Privacy | 1 | 2024 | 41 | 0.200 |
Why?
| | Aged | 18 | 2021 | 26212 | 0.200 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1154 | 0.200 |
Why?
| | Aromatherapy | 1 | 2023 | 2 | 0.200 |
Why?
| | Clinical Competence | 3 | 2018 | 1247 | 0.200 |
Why?
| | Pregnancy Trimester, Second | 4 | 2018 | 84 | 0.200 |
Why?
| | Scapula | 1 | 2024 | 48 | 0.200 |
Why?
| | Contraceptive Devices | 1 | 2023 | 3 | 0.200 |
Why?
| | Ethinyl Estradiol | 1 | 2023 | 16 | 0.200 |
Why?
| | Pediatricians | 1 | 2024 | 121 | 0.200 |
Why?
| | Birth Weight | 1 | 2006 | 517 | 0.200 |
Why?
| | Cost-Benefit Analysis | 3 | 2020 | 644 | 0.190 |
Why?
| | Telemedicine | 2 | 2023 | 963 | 0.190 |
Why?
| | Social Support | 2 | 2020 | 650 | 0.190 |
Why?
| | Patient Health Questionnaire | 1 | 2023 | 40 | 0.190 |
Why?
| | Fellowships and Scholarships | 2 | 2018 | 354 | 0.190 |
Why?
| | Device Removal | 1 | 2024 | 142 | 0.190 |
Why?
| | Fertility | 3 | 2023 | 174 | 0.190 |
Why?
| | Physician's Role | 1 | 2024 | 225 | 0.190 |
Why?
| | Pain | 2 | 2018 | 791 | 0.190 |
Why?
| | Leuprolide | 1 | 2022 | 21 | 0.190 |
Why?
| | Decision Making | 4 | 2016 | 981 | 0.190 |
Why?
| | House Calls | 2 | 2019 | 154 | 0.190 |
Why?
| | Pediatrics | 2 | 2024 | 1124 | 0.190 |
Why?
| | Semen | 1 | 2022 | 24 | 0.180 |
Why?
| | Abortion, Spontaneous | 1 | 2023 | 119 | 0.180 |
Why?
| | Pregnancy Tests | 2 | 2017 | 11 | 0.180 |
Why?
| | Patient Preference | 2 | 2015 | 223 | 0.180 |
Why?
| | Exercise | 3 | 2024 | 2203 | 0.170 |
Why?
| | Treatment Adherence and Compliance | 1 | 2021 | 27 | 0.170 |
Why?
| | Infant, Newborn | 8 | 2025 | 6464 | 0.170 |
Why?
| | Chorioamnionitis | 1 | 2021 | 50 | 0.170 |
Why?
| | Students, Medical | 2 | 2016 | 378 | 0.160 |
Why?
| | beta Catenin | 2 | 2022 | 254 | 0.160 |
Why?
| | Maternal-Child Health Services | 1 | 2020 | 12 | 0.160 |
Why?
| | Pilot Projects | 4 | 2024 | 1897 | 0.160 |
Why?
| | Lymph Node Excision | 3 | 2018 | 173 | 0.160 |
Why?
| | Decision Support Techniques | 2 | 2020 | 479 | 0.160 |
Why?
| | Parturition | 2 | 2019 | 69 | 0.160 |
Why?
| | Self Report | 3 | 2021 | 875 | 0.160 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 1999 | 39 | 0.160 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 125 | 0.160 |
Why?
| | Magnetics | 2 | 1999 | 46 | 0.160 |
Why?
| | Accelerometry | 1 | 2021 | 118 | 0.150 |
Why?
| | Home Health Nursing | 1 | 2019 | 13 | 0.150 |
Why?
| | Patient Education as Topic | 3 | 2019 | 777 | 0.150 |
Why?
| | Uterine Hemorrhage | 2 | 2021 | 41 | 0.150 |
Why?
| | Menstruation Disturbances | 1 | 2019 | 13 | 0.150 |
Why?
| | Health Facilities | 1 | 2020 | 85 | 0.150 |
Why?
| | Pharmacogenetics | 1 | 2021 | 175 | 0.150 |
Why?
| | Outpatients | 3 | 2023 | 447 | 0.150 |
Why?
| | Factor Analysis, Statistical | 1 | 2020 | 291 | 0.150 |
Why?
| | Hysterectomy, Vaginal | 1 | 2019 | 6 | 0.150 |
Why?
| | Cytochrome P450 Family 3 | 1 | 2019 | 3 | 0.150 |
Why?
| | Dietary Supplements | 1 | 2023 | 584 | 0.150 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2017 | 79 | 0.150 |
Why?
| | Body Mass Index | 5 | 2024 | 2447 | 0.150 |
Why?
| | Vaginosis, Bacterial | 1 | 2019 | 10 | 0.150 |
Why?
| | Cues | 1 | 2022 | 329 | 0.150 |
Why?
| | Candidiasis, Vulvovaginal | 1 | 2019 | 5 | 0.150 |
Why?
| | Insulin Resistance | 2 | 2008 | 1244 | 0.150 |
Why?
| | Clothing | 1 | 2019 | 23 | 0.150 |
Why?
| | Hygiene | 1 | 2019 | 29 | 0.150 |
Why?
| | Transgender Persons | 1 | 2022 | 210 | 0.140 |
Why?
| | Neoplasm Staging | 6 | 2020 | 1474 | 0.140 |
Why?
| | Double-Blind Method | 5 | 2018 | 2064 | 0.140 |
Why?
| | Anesthesia, Inhalation | 1 | 2018 | 14 | 0.140 |
Why?
| | Anesthesia, Intravenous | 1 | 2018 | 24 | 0.140 |
Why?
| | Cancer Pain | 1 | 2019 | 39 | 0.140 |
Why?
| | Live Birth | 1 | 2019 | 81 | 0.140 |
Why?
| | Obesity | 5 | 2016 | 3118 | 0.140 |
Why?
| | Medical Oncology | 2 | 2019 | 340 | 0.140 |
Why?
| | Nitrous Oxide | 1 | 2018 | 34 | 0.140 |
Why?
| | Anesthetics, Intravenous | 1 | 2018 | 69 | 0.140 |
Why?
| | Models, Anatomic | 1 | 2019 | 87 | 0.140 |
Why?
| | Genitalia, Female | 1 | 2018 | 42 | 0.140 |
Why?
| | Physician Assistants | 1 | 2020 | 101 | 0.140 |
Why?
| | Databases, Factual | 3 | 2021 | 1491 | 0.140 |
Why?
| | Databases as Topic | 2 | 2008 | 71 | 0.140 |
Why?
| | Anesthetics, Inhalation | 1 | 2018 | 52 | 0.140 |
Why?
| | Hemostasis, Surgical | 2 | 2016 | 25 | 0.140 |
Why?
| | Treatment Outcome | 10 | 2020 | 11793 | 0.140 |
Why?
| | Ovariectomy | 2 | 2015 | 166 | 0.130 |
Why?
| | Organ Transplantation | 1 | 2021 | 253 | 0.130 |
Why?
| | Off-Label Use | 1 | 2018 | 51 | 0.130 |
Why?
| | Risk-Taking | 2 | 2019 | 323 | 0.130 |
Why?
| | Culture | 1 | 2019 | 124 | 0.130 |
Why?
| | Conflict of Interest | 1 | 2018 | 54 | 0.130 |
Why?
| | Nurse Practitioners | 1 | 2020 | 141 | 0.130 |
Why?
| | Logistic Models | 6 | 2024 | 2139 | 0.130 |
Why?
| | Oncologists | 1 | 2018 | 47 | 0.130 |
Why?
| | Psychometrics | 4 | 2009 | 731 | 0.130 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2018 | 103 | 0.130 |
Why?
| | Adenocarcinoma | 2 | 2015 | 926 | 0.130 |
Why?
| | Commerce | 1 | 2018 | 80 | 0.130 |
Why?
| | Sterilization, Reproductive | 1 | 2017 | 8 | 0.130 |
Why?
| | Demyelinating Diseases | 1 | 1998 | 84 | 0.130 |
Why?
| | Hysteroscopy | 1 | 2017 | 14 | 0.130 |
Why?
| | Quality of Health Care | 2 | 2021 | 693 | 0.130 |
Why?
| | Polymorphism, Genetic | 1 | 2019 | 615 | 0.130 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2018 | 76 | 0.120 |
Why?
| | Professional-Patient Relations | 1 | 2018 | 147 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 1969 | 0.120 |
Why?
| | Salpingectomy | 2 | 2015 | 15 | 0.120 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2017 | 30 | 0.120 |
Why?
| | Abortion, Therapeutic | 1 | 2016 | 3 | 0.120 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 210 | 0.120 |
Why?
| | Brain Diseases | 1 | 1998 | 155 | 0.120 |
Why?
| | Dilatation and Curettage | 1 | 2016 | 13 | 0.120 |
Why?
| | Ultrasonography | 2 | 2019 | 788 | 0.120 |
Why?
| | Incidence | 5 | 2019 | 2933 | 0.120 |
Why?
| | Pelvic Infection | 1 | 2016 | 6 | 0.120 |
Why?
| | Surgeons | 2 | 2018 | 340 | 0.120 |
Why?
| | Family | 1 | 2021 | 684 | 0.120 |
Why?
| | Bipolar Disorder | 1 | 1999 | 291 | 0.120 |
Why?
| | Medical Marijuana | 1 | 2018 | 122 | 0.120 |
Why?
| | Minority Groups | 1 | 2018 | 285 | 0.120 |
Why?
| | Tissue Adhesives | 1 | 2016 | 21 | 0.120 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2017 | 75 | 0.120 |
Why?
| | Follow-Up Studies | 8 | 2019 | 5428 | 0.120 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2015 | 33 | 0.120 |
Why?
| | Pregnancy, Unwanted | 1 | 2015 | 15 | 0.120 |
Why?
| | Weight Reduction Programs | 1 | 2017 | 140 | 0.120 |
Why?
| | Cerebral Cortex | 1 | 1999 | 474 | 0.110 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 329 | 0.110 |
Why?
| | Risk Reduction Behavior | 2 | 2014 | 217 | 0.110 |
Why?
| | Administration, Cutaneous | 1 | 2015 | 127 | 0.110 |
Why?
| | Infant | 3 | 2023 | 10089 | 0.110 |
Why?
| | Internet | 2 | 2019 | 693 | 0.110 |
Why?
| | Patient Compliance | 2 | 2012 | 588 | 0.110 |
Why?
| | Placebos | 1 | 2015 | 193 | 0.110 |
Why?
| | Ambulatory Care | 1 | 2020 | 610 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 7 | 2001 | 3915 | 0.110 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1998 | 627 | 0.110 |
Why?
| | Interpersonal Relations | 2 | 2017 | 398 | 0.110 |
Why?
| | Contraceptives, Oral | 1 | 2015 | 37 | 0.110 |
Why?
| | Hot Flashes | 1 | 2015 | 92 | 0.110 |
Why?
| | Papillomaviridae | 1 | 2015 | 116 | 0.110 |
Why?
| | Radiography, Thoracic | 1 | 2016 | 172 | 0.110 |
Why?
| | Anticoagulants | 1 | 2020 | 748 | 0.110 |
Why?
| | Physician-Patient Relations | 2 | 2019 | 588 | 0.110 |
Why?
| | Abdominal Abscess | 1 | 2014 | 26 | 0.110 |
Why?
| | Advanced Practice Nursing | 1 | 2015 | 45 | 0.110 |
Why?
| | Delayed-Action Preparations | 1 | 2015 | 189 | 0.100 |
Why?
| | Curriculum | 3 | 2018 | 1074 | 0.100 |
Why?
| | Pandemics | 1 | 2023 | 1711 | 0.100 |
Why?
| | Risk Factors | 10 | 2022 | 10916 | 0.100 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 196 | 0.100 |
Why?
| | Immunization Schedule | 1 | 2015 | 186 | 0.100 |
Why?
| | Schizophrenia | 4 | 2000 | 464 | 0.100 |
Why?
| | Genetic Variation | 1 | 2019 | 976 | 0.100 |
Why?
| | Glycoproteins | 1 | 2015 | 354 | 0.100 |
Why?
| | Neoplasm Grading | 3 | 2022 | 311 | 0.100 |
Why?
| | Endometrium | 1 | 2014 | 64 | 0.100 |
Why?
| | Digoxin | 1 | 2013 | 27 | 0.100 |
Why?
| | Fatigue | 1 | 2015 | 365 | 0.100 |
Why?
| | Otolaryngology | 1 | 2015 | 108 | 0.100 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2013 | 19 | 0.100 |
Why?
| | Pelvic Neoplasms | 1 | 2013 | 24 | 0.100 |
Why?
| | Umbilical Cord | 1 | 2013 | 93 | 0.100 |
Why?
| | Robotics | 1 | 2014 | 90 | 0.100 |
Why?
| | Motivational Interviewing | 1 | 2014 | 121 | 0.090 |
Why?
| | Brain | 8 | 2001 | 2969 | 0.090 |
Why?
| | Peer Group | 1 | 2015 | 255 | 0.090 |
Why?
| | Antigens, CD | 1 | 2015 | 558 | 0.090 |
Why?
| | Travel | 2 | 2024 | 136 | 0.090 |
Why?
| | Overweight | 1 | 2017 | 614 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1150 | 0.090 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2013 | 89 | 0.090 |
Why?
| | Drug Monitoring | 1 | 2015 | 401 | 0.090 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 409 | 0.090 |
Why?
| | School Health Services | 1 | 2014 | 221 | 0.090 |
Why?
| | Guideline Adherence | 2 | 2021 | 587 | 0.080 |
Why?
| | Abortion Applicants | 1 | 2010 | 3 | 0.080 |
Why?
| | Papillomavirus Infections | 1 | 2015 | 344 | 0.080 |
Why?
| | Glucose Tolerance Test | 2 | 2013 | 361 | 0.080 |
Why?
| | Opioid-Related Disorders | 1 | 2019 | 605 | 0.080 |
Why?
| | Hemorrhage | 1 | 2016 | 822 | 0.080 |
Why?
| | Odds Ratio | 2 | 2016 | 1083 | 0.080 |
Why?
| | Rural Population | 3 | 2022 | 660 | 0.080 |
Why?
| | Domestic Violence | 1 | 2010 | 51 | 0.080 |
Why?
| | Anal Canal | 2 | 2022 | 102 | 0.080 |
Why?
| | Health Care Costs | 1 | 2014 | 425 | 0.080 |
Why?
| | Blood Loss, Surgical | 3 | 2016 | 113 | 0.080 |
Why?
| | Education, Medical, Graduate | 1 | 2015 | 562 | 0.080 |
Why?
| | Clinical Clerkship | 1 | 2011 | 109 | 0.080 |
Why?
| | Pain Measurement | 2 | 2025 | 562 | 0.080 |
Why?
| | Pediatric Obesity | 1 | 2017 | 638 | 0.080 |
Why?
| | Peptides | 1 | 2015 | 998 | 0.080 |
Why?
| | Neoplasm Invasiveness | 3 | 2017 | 508 | 0.080 |
Why?
| | Linear Models | 3 | 2019 | 849 | 0.080 |
Why?
| | Misoprostol | 1 | 2009 | 15 | 0.070 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 2009 | 20 | 0.070 |
Why?
| | Latin America | 1 | 2009 | 96 | 0.070 |
Why?
| | Preoperative Care | 3 | 2017 | 380 | 0.070 |
Why?
| | Risk Assessment | 4 | 2016 | 3752 | 0.070 |
Why?
| | Research Design | 1 | 2015 | 1139 | 0.070 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 67 | 0.070 |
Why?
| | Personality Inventory | 1 | 2009 | 134 | 0.070 |
Why?
| | Medical Records Systems, Computerized | 1 | 2009 | 95 | 0.070 |
Why?
| | Interferon-beta | 2 | 2000 | 92 | 0.070 |
Why?
| | Dominance, Cerebral | 2 | 2000 | 56 | 0.070 |
Why?
| | Case-Control Studies | 5 | 2020 | 3634 | 0.070 |
Why?
| | Sleep | 1 | 2015 | 889 | 0.070 |
Why?
| | Referral and Consultation | 2 | 2018 | 868 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2012 | 560 | 0.070 |
Why?
| | Menarche | 1 | 2008 | 53 | 0.070 |
Why?
| | Smoking | 1 | 2015 | 1477 | 0.070 |
Why?
| | Nausea | 2 | 2019 | 112 | 0.070 |
Why?
| | Sex Factors | 6 | 2020 | 2110 | 0.070 |
Why?
| | Multivariate Analysis | 2 | 2025 | 1547 | 0.070 |
Why?
| | Temporal Lobe | 3 | 1997 | 107 | 0.070 |
Why?
| | Breast Feeding | 1 | 2012 | 447 | 0.070 |
Why?
| | Schizophrenia, Paranoid | 2 | 1997 | 9 | 0.070 |
Why?
| | Weight Loss | 2 | 2017 | 859 | 0.070 |
Why?
| | Psychotic Disorders | 2 | 2000 | 192 | 0.060 |
Why?
| | Comorbidity | 2 | 2016 | 1662 | 0.060 |
Why?
| | Reference Values | 3 | 2018 | 798 | 0.060 |
Why?
| | Societies, Medical | 3 | 2018 | 900 | 0.060 |
Why?
| | Students, Health Occupations | 1 | 2007 | 37 | 0.060 |
Why?
| | Healthy Volunteers | 2 | 2019 | 219 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 534 | 0.060 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 96 | 0.060 |
Why?
| | Fathers | 1 | 2006 | 53 | 0.060 |
Why?
| | False Positive Reactions | 1 | 2006 | 123 | 0.060 |
Why?
| | Science | 1 | 2007 | 55 | 0.060 |
Why?
| | Auditory Cortex | 2 | 1997 | 46 | 0.060 |
Why?
| | Urethritis | 1 | 2005 | 4 | 0.060 |
Why?
| | Prognosis | 4 | 2018 | 4329 | 0.060 |
Why?
| | Azithromycin | 1 | 2006 | 101 | 0.060 |
Why?
| | Uterine Cervical Diseases | 1 | 2005 | 6 | 0.060 |
Why?
| | Maternal Health Services | 1 | 2007 | 101 | 0.060 |
Why?
| | Self Efficacy | 2 | 2019 | 411 | 0.060 |
Why?
| | Prevalence | 2 | 2017 | 2874 | 0.060 |
Why?
| | Fatty Liver | 1 | 2008 | 253 | 0.060 |
Why?
| | Length of Stay | 3 | 2015 | 1350 | 0.060 |
Why?
| | Dilatation | 1 | 2025 | 73 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 1998 | 2393 | 0.050 |
Why?
| | Chronic Disease | 2 | 2024 | 1810 | 0.050 |
Why?
| | Teaching | 1 | 2007 | 237 | 0.050 |
Why?
| | Metformin | 1 | 2008 | 329 | 0.050 |
Why?
| | Herb-Drug Interactions | 1 | 2023 | 4 | 0.050 |
Why?
| | Metabolic Syndrome | 1 | 2008 | 361 | 0.050 |
Why?
| | Acanthosis Nigricans | 1 | 2003 | 4 | 0.050 |
Why?
| | Hospitals, University | 2 | 2016 | 176 | 0.050 |
Why?
| | Texas | 1 | 2024 | 273 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2015 | 1270 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2008 | 1512 | 0.050 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2023 | 5 | 0.050 |
Why?
| | Biomarkers, Tumor | 2 | 2022 | 1329 | 0.050 |
Why?
| | Ovulation | 1 | 2023 | 46 | 0.050 |
Why?
| | Urban Population | 2 | 2016 | 494 | 0.050 |
Why?
| | Program Evaluation | 2 | 2019 | 943 | 0.050 |
Why?
| | Rifampin | 1 | 2023 | 79 | 0.050 |
Why?
| | Diet | 2 | 2024 | 1278 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2667 | 0.050 |
Why?
| | Episiotomy | 1 | 2022 | 5 | 0.050 |
Why?
| | Longitudinal Studies | 3 | 2017 | 2967 | 0.040 |
Why?
| | Pregnancy, Twin | 1 | 2021 | 19 | 0.040 |
Why?
| | Anxiety | 2 | 2019 | 1122 | 0.040 |
Why?
| | Menstrual Cycle | 1 | 2022 | 145 | 0.040 |
Why?
| | Pain Management | 1 | 2025 | 411 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2021 | 35 | 0.040 |
Why?
| | Neoplasms | 1 | 2016 | 2913 | 0.040 |
Why?
| | Reproduction | 1 | 2022 | 208 | 0.040 |
Why?
| | Alpha Rhythm | 1 | 2000 | 11 | 0.040 |
Why?
| | Anti-Bacterial Agents | 2 | 2014 | 1925 | 0.040 |
Why?
| | Analysis of Variance | 5 | 2005 | 1300 | 0.040 |
Why?
| | Time-to-Pregnancy | 1 | 2020 | 3 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 50 | 0.040 |
Why?
| | Biomedical Research | 1 | 2007 | 719 | 0.040 |
Why?
| | Wrist | 1 | 2021 | 60 | 0.040 |
Why?
| | Coitus | 2 | 2011 | 24 | 0.040 |
Why?
| | Mother-Child Relations | 1 | 2021 | 131 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2019 | 20 | 0.040 |
Why?
| | Refractory Period, Electrophysiological | 1 | 1999 | 5 | 0.040 |
Why?
| | Ethics, Medical | 1 | 2020 | 91 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2019 | 27 | 0.040 |
Why?
| | Poverty | 2 | 2017 | 528 | 0.040 |
Why?
| | Median Nerve | 1 | 1999 | 26 | 0.040 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 69 | 0.040 |
Why?
| | Needs Assessment | 2 | 2015 | 402 | 0.040 |
Why?
| | Ethics, Institutional | 1 | 2019 | 4 | 0.040 |
Why?
| | Visible Human Projects | 1 | 2019 | 2 | 0.040 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2000 | 83 | 0.040 |
Why?
| | Mutation | 2 | 2022 | 4090 | 0.040 |
Why?
| | Reproducibility of Results | 3 | 2023 | 3416 | 0.040 |
Why?
| | Neural Inhibition | 1 | 2000 | 178 | 0.040 |
Why?
| | Genital Diseases, Female | 1 | 2019 | 31 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 33 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 35 | 0.040 |
Why?
| | Reproductive Health Services | 1 | 2019 | 19 | 0.040 |
Why?
| | Tissue Donors | 1 | 2022 | 420 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 55 | 0.040 |
Why?
| | Pituitary Gland | 1 | 1999 | 149 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2000 | 244 | 0.040 |
Why?
| | Biological Variation, Population | 1 | 2018 | 21 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2018 | 79 | 0.040 |
Why?
| | Electroencephalography | 2 | 1999 | 563 | 0.040 |
Why?
| | Testosterone | 1 | 2022 | 416 | 0.030 |
Why?
| | Operative Time | 1 | 2019 | 181 | 0.030 |
Why?
| | Morning Sickness | 1 | 2018 | 3 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 108 | 0.030 |
Why?
| | Electric Stimulation | 1 | 1999 | 277 | 0.030 |
Why?
| | Midazolam | 1 | 2018 | 73 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2008 | 1399 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2023 | 2000 | 0.030 |
Why?
| | Psychology, Adolescent | 2 | 2008 | 61 | 0.030 |
Why?
| | Carmustine | 1 | 1998 | 52 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1482 | 0.030 |
Why?
| | Memory, Short-Term | 1 | 2000 | 269 | 0.030 |
Why?
| | Memory | 2 | 1999 | 297 | 0.030 |
Why?
| | Frozen Sections | 1 | 2018 | 24 | 0.030 |
Why?
| | Patient Care | 1 | 2019 | 120 | 0.030 |
Why?
| | Aspartic Acid | 1 | 1998 | 88 | 0.030 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 165 | 0.030 |
Why?
| | Thalamus | 1 | 1999 | 129 | 0.030 |
Why?
| | Creatine | 1 | 1998 | 63 | 0.030 |
Why?
| | Legislation, Drug | 1 | 2018 | 73 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 770 | 0.030 |
Why?
| | Hysterosalpingography | 1 | 2017 | 9 | 0.030 |
Why?
| | Fentanyl | 1 | 2018 | 128 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2019 | 244 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 1998 | 272 | 0.030 |
Why?
| | Sterilization, Tubal | 1 | 2017 | 17 | 0.030 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 2219 | 0.030 |
Why?
| | Hippocampus | 2 | 2001 | 973 | 0.030 |
Why?
| | Transcription Factors | 1 | 2005 | 1736 | 0.030 |
Why?
| | Health Surveys | 1 | 2019 | 520 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1378 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 467 | 0.030 |
Why?
| | Hospitals, Private | 1 | 2016 | 12 | 0.030 |
Why?
| | Health Facility Size | 1 | 2016 | 13 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 1998 | 427 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 2094 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2016 | 89 | 0.030 |
Why?
| | AC133 Antigen | 1 | 2015 | 20 | 0.030 |
Why?
| | Marijuana Abuse | 1 | 2019 | 214 | 0.030 |
Why?
| | Self Care | 1 | 2019 | 392 | 0.030 |
Why?
| | Indians, North American | 1 | 2021 | 598 | 0.030 |
Why?
| | Medical Audit | 1 | 2016 | 77 | 0.030 |
Why?
| | Cisplatin | 1 | 1998 | 345 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2016 | 121 | 0.030 |
Why?
| | Marriage | 1 | 2017 | 121 | 0.030 |
Why?
| | Radiotherapy | 1 | 2016 | 206 | 0.030 |
Why?
| | Brain Injuries | 1 | 2001 | 507 | 0.030 |
Why?
| | Reaction Time | 4 | 2000 | 434 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2016 | 189 | 0.030 |
Why?
| | Patient Simulation | 1 | 2015 | 43 | 0.030 |
Why?
| | North America | 1 | 2016 | 303 | 0.030 |
Why?
| | Ileus | 1 | 2015 | 13 | 0.030 |
Why?
| | Cell Count | 1 | 2015 | 319 | 0.030 |
Why?
| | Urinary Retention | 1 | 2015 | 24 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2006 | 528 | 0.030 |
Why?
| | Income | 1 | 2016 | 203 | 0.030 |
Why?
| | Terminal Care | 1 | 2019 | 283 | 0.030 |
Why?
| | Competitive Behavior | 1 | 2015 | 43 | 0.030 |
Why?
| | Female Urogenital Diseases | 1 | 2014 | 7 | 0.030 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2014 | 29 | 0.030 |
Why?
| | Natural Family Planning Methods | 1 | 2014 | 2 | 0.030 |
Why?
| | Morbidity | 1 | 2015 | 322 | 0.030 |
Why?
| | Receptors, Androgen | 1 | 2015 | 149 | 0.030 |
Why?
| | Elective Surgical Procedures | 1 | 2016 | 203 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2014 | 30 | 0.030 |
Why?
| | Memory Disorders | 1 | 1996 | 197 | 0.030 |
Why?
| | Laparoscopy | 1 | 2019 | 481 | 0.030 |
Why?
| | Blood Volume | 1 | 2014 | 65 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2015 | 157 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2015 | 244 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2933 | 0.030 |
Why?
| | Acoustic Stimulation | 3 | 2000 | 333 | 0.030 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 303 | 0.030 |
Why?
| | Homosexuality, Male | 1 | 1995 | 231 | 0.030 |
Why?
| | Pelvis | 1 | 2015 | 125 | 0.030 |
Why?
| | Surgical Procedures, Operative | 1 | 2016 | 271 | 0.020 |
Why?
| | Vagina | 1 | 2016 | 203 | 0.020 |
Why?
| | Administration, Intravaginal | 1 | 2013 | 19 | 0.020 |
Why?
| | Hemostatics | 1 | 2014 | 64 | 0.020 |
Why?
| | Personnel Selection | 1 | 2015 | 91 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1998 | 2028 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 2181 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 782 | 0.020 |
Why?
| | Disease Progression | 2 | 2017 | 2865 | 0.020 |
Why?
| | Drainage | 1 | 2014 | 185 | 0.020 |
Why?
| | Insurance, Health | 1 | 2016 | 311 | 0.020 |
Why?
| | Child Development | 1 | 1998 | 483 | 0.020 |
Why?
| | Educational Measurement | 1 | 2016 | 326 | 0.020 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 404 | 0.020 |
Why?
| | Patient Readmission | 1 | 2018 | 772 | 0.020 |
Why?
| | Insulin | 1 | 2003 | 2516 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2014 | 536 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2019 | 1166 | 0.020 |
Why?
| | Alcoholism | 1 | 1999 | 826 | 0.020 |
Why?
| | Multiple Sclerosis | 1 | 1998 | 489 | 0.020 |
Why?
| | Perception | 1 | 2015 | 378 | 0.020 |
Why?
| | Text Messaging | 1 | 2014 | 182 | 0.020 |
Why?
| | Escherichia coli | 1 | 2016 | 835 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 1998 | 699 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 4302 | 0.020 |
Why?
| | Specialty Boards | 1 | 2011 | 42 | 0.020 |
Why?
| | Phenotype | 1 | 1999 | 3170 | 0.020 |
Why?
| | Faculty | 1 | 2011 | 148 | 0.020 |
Why?
| | Registries | 1 | 2019 | 2410 | 0.020 |
Why?
| | Medicaid | 1 | 2014 | 467 | 0.020 |
Why?
| | Interferon beta-1a | 2 | 2000 | 14 | 0.020 |
Why?
| | New York City | 1 | 2009 | 84 | 0.020 |
Why?
| | Urban Health Services | 1 | 2009 | 69 | 0.020 |
Why?
| | Physicians | 1 | 2018 | 956 | 0.020 |
Why?
| | Gravidity | 1 | 2008 | 7 | 0.020 |
Why?
| | Students | 1 | 2014 | 652 | 0.020 |
Why?
| | Injections, Intramuscular | 2 | 2000 | 146 | 0.020 |
Why?
| | Southwestern United States | 1 | 2008 | 93 | 0.020 |
Why?
| | Cross-Cultural Comparison | 1 | 2008 | 84 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 995 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 3551 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 3210 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2011 | 911 | 0.020 |
Why?
| | Cholesterol, HDL | 1 | 2008 | 201 | 0.020 |
Why?
| | Puberty | 1 | 2008 | 137 | 0.020 |
Why?
| | Aging | 1 | 1998 | 1973 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2443 | 0.020 |
Why?
| | Medical Indigency | 1 | 2006 | 11 | 0.020 |
Why?
| | Urine | 1 | 2007 | 64 | 0.020 |
Why?
| | Social Perception | 1 | 2008 | 103 | 0.020 |
Why?
| | Urinalysis | 1 | 2007 | 83 | 0.020 |
Why?
| | Research Support as Topic | 1 | 2007 | 81 | 0.020 |
Why?
| | Forecasting | 1 | 2008 | 390 | 0.020 |
Why?
| | Education | 1 | 2007 | 105 | 0.020 |
Why?
| | Social Environment | 1 | 2008 | 252 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2007 | 148 | 0.010 |
Why?
| | Health Services Needs and Demand | 1 | 2008 | 280 | 0.010 |
Why?
| | Child, Preschool | 1 | 2021 | 11866 | 0.010 |
Why?
| | Hospitalization | 1 | 2016 | 2460 | 0.010 |
Why?
| | Triglycerides | 1 | 2008 | 520 | 0.010 |
Why?
| | Universities | 1 | 2007 | 445 | 0.010 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2004 | 33 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2770 | 0.010 |
Why?
| | Attention | 2 | 1999 | 463 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2005 | 368 | 0.010 |
Why?
| | Self Concept | 1 | 2005 | 254 | 0.010 |
Why?
| | Sex Characteristics | 2 | 1999 | 789 | 0.010 |
Why?
| | Research | 1 | 2005 | 431 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2005 | 1330 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 2 | 1997 | 782 | 0.010 |
Why?
| | Blood Pressure | 1 | 2008 | 1782 | 0.010 |
Why?
| | Electromagnetic Fields | 1 | 1999 | 37 | 0.010 |
Why?
| | Schizophrenic Psychology | 1 | 1999 | 99 | 0.010 |
Why?
| | Wechsler Scales | 1 | 1998 | 61 | 0.010 |
Why?
| | Blood Glucose | 1 | 2008 | 2344 | 0.010 |
Why?
| | Sound Localization | 1 | 1998 | 61 | 0.010 |
Why?
| | Gadolinium | 1 | 1998 | 84 | 0.010 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 1999 | 288 | 0.010 |
Why?
| | Cognition | 1 | 2005 | 1271 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1999 | 484 | 0.010 |
Why?
| | Least-Squares Analysis | 1 | 1995 | 73 | 0.010 |
Why?
| | Confidence Intervals | 1 | 1996 | 330 | 0.010 |
Why?
| | Verbal Behavior | 1 | 1995 | 42 | 0.010 |
Why?
| | Space Perception | 1 | 1995 | 82 | 0.010 |
Why?
| | Cognition Disorders | 1 | 1999 | 544 | 0.010 |
Why?
| | Recurrence | 1 | 1998 | 1139 | 0.010 |
Why?
| | Software | 1 | 1999 | 680 | 0.010 |
Why?
|
|
Sheeder's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|